212. 三尖弁閉鎖症
［臨床試験数：6，薬物数：8（DrugBank：7），標的遺伝子数：8，標的パスウェイ数：12］
Searched query = "Tricuspid atresia", "TA"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04176458 (ClinicalTrials.gov) | April 21, 2019 | 12/2/2019 | Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease | Non-invasive Assessment of Liver Function in Patients Undergoing Heart and Liver Transplant Evaluation | Dilated Cardiomyopathy;Tricuspid Atresia | Device: Methacetin Breath Test (MBT) | Northwestern University | NULL | Recruiting | 18 Years | N/A | All | 20 | N/A | United States |
| 2 | NCT01292551 (ClinicalTrials.gov) | February 2011 | 8/2/2011 | Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology. | Treatment With Endothelin Antagonist to Tcpc Patients; a Multicenter, Randomized, Prospective Study Measuring Maximal O2 Uptake in Ergometer Bicycle Test | Hypoplastic Left Heart Syndrome;Tricuspid Atresia;Other Specified Congenital Anomalies of Heart | Drug: Bosentan;Drug: Placebo | Rigshospitalet, Denmark | Aarhus University Hospital;Bispebjerg Hospital;Actelion | Completed | 15 Years | N/A | Both | 75 | Phase 2 | Denmark;Sweden |
| 3 | NCT00974025 (ClinicalTrials.gov) | June 2009 | 9/9/2009 | Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients | Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation | Fontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid Atresia | Dietary Supplement: Vitamin C;Dietary Supplement: Placebo | University of Michigan | Griese-Hutchinson Champions for Children's Hearts Investigator Award | Completed | 8 Years | 25 Years | All | 53 | N/A | United States |
| 4 | NCT00507819 (ClinicalTrials.gov) | December 2007 | 25/7/2007 | Sildenafil After the Fontan Operation | The Sildenafil After Fontan Operation Study | Hypoplastic Left Heart Syndrome;Tricuspid Atresia | Drug: Sildenafil;Drug: Placebo | Children's Hospital of Philadelphia | The Mark H. and Blanche M. Harrington Foundation | Completed | 8 Years | 40 Years | All | 28 | Phase 2 | United States |
| 5 | NCT00573066 (ClinicalTrials.gov) | May 2004 | 11/12/2007 | Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery | The Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac Surgery | Hypoplastic Left Heart;Tetralogy of Fallot;Tricuspid Atresia | Drug: Dexmedetomidine | Athena Zuppa | NULL | Completed | 1 Month | 24 Months | All | 56 | Phase 1 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00004828 (ClinicalTrials.gov) | December 1994 | 24/2/2000 | Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure | Tricuspid Atresia;Heart Defects, Congenital | Drug: liothyronine I 131 | FDA Office of Orphan Products Development | Children's Hospital and Health Center | Completed | N/A | 17 Years | Both | 28 | Phase 1 | NULL |